Dashboard
Manage Tickers

AXSMAxsome Therapeutics, Inc.

Nasdaq axsome.com


$ 88.05 $ 0.88 (1.01 %)    

Friday, 23-Aug-2024 15:59:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 87.99
$ 87.17
$ 87.91 x 100
-- x --
$ 86.68 - $ 88.17
$ 55.02 - $ 98.40
329,786
na
4.22B
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 02-23-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-07-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-02-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-15-2019 12-31-2018 10-K
24 11-09-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 03-07-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-07-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-11-2016 03-31-2016 10-Q
35 03-24-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

unveiling-14-analyst-insights-on-axsome-therapeutics
Unveiling 14 Analyst Insights On Axsome Th...
08/22/2024 14:00:14

hc-wainwright--co-reiterates-buy-on-axsome-therapeutics-maintains-180-price-target
HC Wainwright & Co. Reiterates Buy on Axso...
08/22/2024 13:23:55

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $18...

axsome-therapeutics-reaches-agreement-with-sandoz-to-dismiss-sunosi-patent-litigation
Axsome Therapeutics Reaches Agreement With...
08/21/2024 11:01:44

ubs-maintains-buy-on-axsome-therapeutics-lowers-price-target-to-105
UBS Maintains Buy on Axsome Therapeutics, ...
08/06/2024 15:32:44

UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $107 to $105.

lithia-motors-to-rally-around-14-here-are-10-top-analyst-forecasts-for-tuesday
Lithia Motors To Rally Around 14%? Here Ar...
08/06/2024 14:06:32

rbc-capital-maintains-outperform-on-axsome-therapeutics-lowers-price-target-to-130
RBC Capital Maintains Outperform on Axsome...
08/06/2024 12:38:01

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price targe...

hc-wainwright--co-maintains-buy-on-axsome-therapeutics-lowers-price-target-to-180
HC Wainwright & Co. Maintains Buy on Axsom...
08/06/2024 11:08:22

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the pri...

b-of-a-securities-upgrades-axsome-therapeutics-to-buy-raises-price-target-to-106
B of A Securities Upgrades Axsome Therapeu...
08/06/2024 10:24:49

B of A Securities analyst Jason Gerberry upgrades Axsome Therapeutics (NASDAQ:AXSM) from Neutral to Buy and raises the price...

needham-reiterates-buy-on-axsome-therapeutics-maintains-130-price-target
Needham Reiterates Buy on Axsome Therapeut...
08/06/2024 10:06:29

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.

a-glimpse-into-the-expert-outlook-on-axsome-therapeutics-through-9-analysts
A Glimpse Into The Expert Outlook On Axsom...
08/05/2024 17:00:39

needham-reiterates-buy-on-axsome-therapeutics-maintains-130-price-target
Needham Reiterates Buy on Axsome Therapeut...
08/05/2024 16:57:56

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $130 price target.

axsome-therapeutics-q2-2024-adj-eps-112-beats-134-estimate
Axsome Therapeutics Q2 2024 Adj. EPS $(1.1...
08/05/2024 11:12:25

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.12) per share which beat the analyst consensus estimate of $...

axsome-therapeutics-says-current-cash-is-sufficient-to-fund-anticipated-operations-into-cash-flow-positivity-based-on-current-operating-plan
Axsome Therapeutics Says Current Cash Is S...
08/05/2024 11:03:03

axsome-therapeutics-q2-sales-87166m-beat-86659m-estimate
Axsome Therapeutics Q2 Sales $87.166M Beat...
08/05/2024 11:01:35

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly sales of $87.166 million which beat the analyst consensus estimate of $86....

cantor-fitzgerald-reiterates-overweight-on-axsome-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/26/2024 17:22:29

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...

jim-cramer-calls-axsome-a-double-or-nothing-stock-says-sap-is-incredible
Jim Cramer Calls Axsome A 'Double Or Nothi...
07/24/2024 13:25:29

Jim Cramer discusses Torm, Trane, Sap and Axsome Therapeutics on CNBC's "Mad Money Lightning Round."

axsome-therapeutics-cns-portfolio-poised-for-major-growth---analyst-predicts-strong-future
Axsome Therapeutics' CNS Portfolio Poised ...
07/22/2024 19:06:24

Needham initiated coverage on Axsome Therapeutics, highlighting its diverse CNS portfolio. The analyst predicts an 8-10x risk-a...

rbc-capital-reiterates-outperform-on-axsome-therapeutics-maintains-131-price-target
RBC Capital Reiterates Outperform on Axsom...
07/22/2024 13:54:17

RBC Capital analyst Leonid Timashev reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and maintains $131 price ...

needham-initiates-coverage-on-axsome-therapeutics-with-buy-rating-announces-price-target-of-130
Needham Initiates Coverage On Axsome Thera...
07/22/2024 09:34:31

Needham analyst Ami Fadia initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and announces Price Targ...

decoding-9-analyst-evaluations-for-axsome-therapeutics
Decoding 9 Analyst Evaluations For Axsome ...
07/18/2024 18:00:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION